NCT04820023View on ClinicalTrials.gov

Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 2, 2021

Primary Completion Date

November 29, 2023

Study Completion Date

November 29, 2023

Conditions
NSCLC
Interventions
DRUG

BBT-176, QD

BBT-176 given orally alone, QD

DRUG

BBT-176, BID

BBT-176 given orally alone, BID

Trial Locations (4)

13605

Seoul National University Bundang Hospital, Seongnam-si

Unknown

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Bridge Biotherapeutics, Inc.

INDUSTRY

NCT04820023 - Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment | Biotech Hunter | Biotech Hunter